Portal de Periódicos da CAPES

Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400

2015; American Association for Cancer Research; Volume: 21; Issue: 7 Linguagem: Inglês

10.1158/1078-0432.ccr-13-3473

1557-3265

Roy S. Herbst, David R. Gandara, Fred R. Hirsch, Mary W. Redman, Michael LeBlanc, Philip C. Mack, Lawrence H. Schwartz, Everett E. Vokes, Suresh S. Ramalingam, Jeffrey D. Bradley, Dana B. Sparks, Yang Zhou, Crystal Miwa, Vincent A. Miller, Roman Yelensky, Yali Li, Jeff Allen, Ellen V. Sigal, David Wholley, Caroline C. Sigman, Gideon M. Blumenthal, Shakun Malik, Gary J. Kelloff, Jeffrey S. Abrams, Charles D. Blanke, Vassiliki A. Papadimitrakopoulou,

Lung Cancer Research Studies

The Lung Master Protocol (Lung-MAP, S1400) is a groundbreaking clinical trial designed to advance the efficient development of targeted therapies for squamous cell carcinoma (SCC) of the lung. There are no approved targeted therapies specific to advanced lung SCC, although The Cancer Genome Atlas project and similar studies have detected a significant number of somatic gene mutations/amplifications in lung SCC, some of which are targetable by investigational agents. However, the frequency of these changes is low (5%-20%), making recruitment and study conduct challenging in the traditional clinical trial setting. Here, we describe our approach to development of a biomarker-driven phase II/II multisubstudy "Master Protocol," using a common platform (next-generation DNA sequencing) to identify actionable molecular abnormalities, followed by randomization to the relevant targeted therapy versus standard of care.